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ABSTRACT  
Objective: This present study was intended to design sustained release tablet containing diclofenac sodium using a matrix of excipient co-
processed xanthan gum-crosslinked amylose.  
Methods: In the previous study, xanthan gum and amylose have been physically and chemically modified by the co-processed and crosslinking 
method, resulting co-processed excipient xanthan gum-crosslinked amylose are Co-CLA6-XG and Co-CLA12-XG (method A); CL6-Co-A-XG and CL12-
Co-A-XG (method B) with each ratio 1:1, 1:2 and 2:1. All excipients had a good swelling index, high viscosity and good gel strength, good 
characteristics to be used as a matrix for sustained release tablet dosage form. In this study, a tablet with excipient Co-CLA6-XG, Co-CLA12-XG, CL6-
Co-A-XG and CL12-Co-A-XG were formulated by direct compression method. The prepared formulations were evaluated for weight variation, 
thickness, and diameter, hardness, friability, drug content estimation, swelling index, in vitro drug release are within the acceptable standard. 
Results: The release profile of diclofenac sodium which contained matrix from Co-CLA6-XG (F1–F3), Co-CLA12-XG (F4–F6), CL6-Co-A-XG (F7–F9) and 
CL12-Co-A-XG (F10–F12) in phospate buffer medium for 8 h, showed that the sustained release profile followed zero order kinetics (F1–F6, F9, F11) and 
Korsmeyer-Peppas (F7, F8, F10, F12). Formula F1 to F6 tablet formulations could be applied as sustained release tablet formula and could retard drug 
release up to 16 h. Then, formula F7 to F12 could be applied as sustained release tablet formula and could retard drug release up to 32 h.  
Conclusion: It may be concluded that coprocessed excipients of crosslinked amylose–xanthan gum can be used for the preparation of sustained 
release tablets of diclofenac sodium and can retard the drug release for 16 h and 32 h.  
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INTRODUCTION  
In recent years, designing of drug products with modified release 
has been done to reduce the frequency of drug administration in 
order to improve patient compliance, reduce fluctuations of drug 
levels in the blood and minimize the side effects of drugs [1, 2]. The 
use of natural polymers for pharmaceutical applications is more 
attractive because of economical, biocompatible, non-toxic, easy to 
chemically modified and potentially biodegradable. Natural 
polysaccharides such as pectin, chitosan, starch (amylose and 
amylopectin), guar gum, xanthan gum and gum karaya commonly 
used in controlled release dosage forms [3]. Nevertheless, based on 
high-amylose starch and xanthan gum chemical structure [4] has 
many hydroxyl groups (-OH) so that the swelling index become fast 
which caused the rapid release of the drug. Therefore, some 
modification (physical, chemical and enzymatically) are required to 
improve the characteristic of starch [5, 6]. Based on the previous 
study, co-processed method (physical modification) and crosslinking 
method (chemical modification) had a good swelling index, high 
viscosity, and good gel strength [7–10]. 
Diclofenac sodium was used as a model drug for patients who have 
osteoarthritis. The main side effects of this drug are nausea, gastritis, 
skin erythema and headache. In addition, this drug has a short half-
life (1-2 h) and oral drug bioavailability approximately 50% due to 
the first-pass metabolism by the liver [11]. It was the basic aim to be 
made into sustained release dosage form that can be sustained levels 
of drug therapy, minimize the frequency of drug administration and 
overcome its side effect. 
MATERIALS AND METHODS 
Materials 
Diclofenac sodium (Yung Zip Chemical, Taiwan), excipient coprocessed 
xanthan gum-crosslinked amylose (Universitas Indonesia, Indonesia), 
Avicel pH 102 (Merck, Germany), aqua dest (Brataco, Indonesia). 
Methods 
Preparations of sustained release matrix tablet of diclofenac 
sodium 
Formulation of sustained release tablet of diclofenac sodium was 
described in table 1. All of these sustained release tablets were 
prepared by direct compression method. Diclofenac sodium, 
excipient co-processed xanthan gum-crosslinked amylose (Co-CLA6-
XG, Co-CLA12-XG, CL6-Co-A-XG and CL12-Co-A-XG) each ratio 1:1, 
1:2 and 2:1 and Avicel pH 102 mixed well for 15 min in a mortar and 
pestle until homogenous. Then compressed into tablets using a 
rotary tablet machine (Korsch, Germany). Furthermore, all tablet 
formulations were evaluated. 
Weight variation 
Twenty tablets from each batch were weighed using an electronic 
balance (Adam AFA–210 LC, USA) together and individually. If 
weighed individually, no more than 2 tablets, which weight deviate 
from the average weight more than a set price column A, and none of 
the weight deviates from the average weight was more than the 
price set column B (table 2) [12]. 
Thickness and diameter 
Randomly drawn 20 tablets individually, diameter and thickness 
was measured using calipers. 
Terms: Unless otherwise stated, the diameter no more than 3 times 
and not less than 1 ⅓ thick tablet [12]. 
Tablet hardness 
This measurement was used to know tablet’s resistance under the 
condition of storage, transportations and handling before usage. The 
hardness of twenty tablets from each batch was checked using 
hardness tester. The hardness was measured in terms of kP. 
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Table 1: Formulation of diclofenac sodium sustained release tablet 
Formula F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 
Diclofenac sodium 75 75 75 75 75 75 75 75 75 75 75 75 75 
Co-CLA6-XG (1:1) 300 - - - - - - - - - - - - 
Co-CLA6-XG (1:2) - 300 - - - - - - - - - - - 
Co-CLA6-XG (2:1) - - 300 - - - - - - - - - - 
Co-CLA12-XG (1:1) - - - 300 - - - - - - - - - 
Co-CLA12-XG (1:2) - - - - 300 - - - - - - - - 
Co-CLA12-XG (2:1) - - - - - 300 - - - - - - - 
CL6-Co-A-XG (1:1) - - - - - - 300 - - - - - - 
CL6-Co-A-XG (1:2) - - - - - - - 300 - - - - - 
CL6-Co-A-XG (2:1) - - - - - - - - 300 - - - - 
CL12-Co-A-XG (1:1) - - - - - - - - - 300 - - - 
CL12-Co-A-XG (1:2) - - - - - - - - - - 300 - - 
CL12-Co-A-XG (2:1) - - - - - - - - - - - 300 - 
Avicel pH 102 125 125 125 125 125 125 125 125 125 125 125 125 425 
Total (mg) 500 500 500 500 500 500 500 500 500 500 500 500 500 
Co-CLA-XG: excipient co-processed amylose crosslinked-xanthan gum (method A), CL-Co-A-XG: excipient co-processed xanthan gum-amylose 
crosslinked (method B), Each batch contains 80 tablets. 
 
Table 2: Weight uniformity limits 
Average weight Average weight Uniformity (%) 
 A B 
25 mg or less 15 30 
26 mg–150 mg 10 20 
150 mg–300 mg 7,5 15 
More than 300 mg 5 10 
 
Friability 
Twenty tablets were weighed and the initial weight of these tablets 
was recorded and placed in friabilator tester and rotated at the 
speed of 25 rpm for 100 revolutions. Then tablets were removed 
from the friabilator, dusted off the fines and again weighed and the 
weight was recorded. 
Friability (%) = 𝑊𝑊1−𝑊𝑊2
𝑊𝑊1
 𝑥𝑥 100%(Eq. 1) 
where:  
W1= weight of the tablet before test 
W2= weight of the tablet after test 
Determination swelling index tablet 
The extent of swelling was measured in terms of percent weight gain 
by the tablet. One tablet from each formulation was kept in a petri 
dish containing 20 ml of phosphate buffer pH 7.4. Swelling index was 
measured by measuring the increase of weight of the tablet for 8 h. 
Measured the weight of the tablet in time intervals (5, 15, 30, 60, 90, 
120, 180, 240, 360, and 480). 
Assay 
Drug content of the sustained release tablet was calculated using UV-
Vis Spectrophotometer. Weighing tablet powder equivalent to 50 mg 
of diclofenac sodium. Subsequently incorporated into 100.0 ml of 
volumetric flask and dissolved with 0.1 N NaOH. Then filtered and 
discarded the first 10 ml of filtrate. The filtrate pipetted 2.0 ml and 
then added to the 100.0 ml volumetric flask with 0.1 N NaOH. 
Measured the wavelength of maximum absorbance (λ 276 nm) [13]. 
The tablet was eligible if it contained diclofenac sodium from 95.0 to 
105.0% of that stated on the label. 
In vitro drug release study 
In vitro drug release study was performed using dissolution test 
apparatus. 
Dissolution test apparatus 
Medium: pH 7.4 phosphate buffer solution 
RPM: 50 
Time: 8 h 
Temp: 37 °C±5 °C 
Volume: 900 ml 
Wavelength: 276 nm 
Procedure: Tablet was introduced into test dissolution apparatus 
and the apparatus was set at 50 rpm. A sample of 10 ml was 
withdrawn at a predetermined time interval (5, 15, 30, 60, 90, 120, 
180, 240, 360, and 600) and replace with fresh medium phosphate 
buffer pH 7.4. Samples were analyzed by UV Spectrophotometer 
(Shimadzu, Japan) at λ 276 nm [14].  
Release Kinetics: Data obtained from in vitro release studied was 
evaluated using the model of release drug kinetics with different 
equations relating to the cumulative amount of drug dissolved (Q) 
against time. The equations use were zero-order kinetics, first-order 
kinetics, Higuchi and Korsmeyer-Peppas as shown in table 3 below 
[2,15]. The goodness of it was evaluated using the correlation 
coefficient values (R2). 
RESULTS AND DISCUSSION 
Excipients Co-CLA-XG and CL-Co-A-XG have been employed to 
formulate sustained release tablets of diclofenac sodium in different 
batch (13 batch). The sustained release tablets were formulated by 
direct compression method based on the formula given in table 1. 
The direct compression method had been chosen because it 
available for any excipient and had a limited number of processing. 
This formulation used Avicel pH 102 as other excipients which have 
functioned as diluent, binder and lubricant.  
The prepared tablets were subjected to all the quality control tests 
that they were within the official pharmacopoeial limits. Weight 
variation test revealed that the tablets were within the range of 
pharmacopoeial limit. The thickness of the tablets was 1.22 mm 
and diameter of the tablets were range from 0.33–0.41 mm. 
Friability is less than 1%, indicated that tablets had a good 
mechanical resistance. The evaluation parameters were within 
acceptable range for all the formulations. The drug content of the 
tablets ranged from 97 % to 99%. The results of hardness, 
friability, weight variation, thickness & diameter and drug content 
were given in table 4. 
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Table 3: Drug release kinetics 
Model Equations 
Zero-order Qt/Q0 = K0. T 
First-order  Ln Qt/Q0 = K1. T 
Higuchi Qt/Q0 = KH. t1/2 
Korsmeyer–Peppas Qt/Q0 = k. tn 
Qt/Q0 = fraction of drug at t time, K0,K1,Kh and k= constant drug release for each equation, n = diffusion’s Peppas exponent 
 
Table 4: Evaluations of diclofenac sodium sustained release tablets* 
Formula % weight variation  Diameter (cm)  Thickness (cm)  Hardness 
(Kp)  
Friability (%)  Drug content (%)  
1 0.11 ± 0.06 1.22 ± 0.00 0.33 ± 0.01 19,.3 ± 0.31 0.68 ± 0.12 98.43 ± 1.39 
2 0.14 ± 0.09 1.22 ± 0.00 0.34  ± 0.01 19.09 ± 0.23 0.70 ± 0.08 98.69 ± 1.72  
3 0.13 ± 0.08 1.22 ± 0.00 0.33  ± 0.00 19.03 ± 0.24 0.62 ± 0.21 97.26 ± 1.78 
4 0.12 ± 0.06 1.22 ± 0.00 0.34  ± 0.01 19.09 ± 0.26 0.70 ± 0.10 97.99 ± 0.89 
5 0.11 ± 0.08 1.22 ± 0.00 0.33  ± 0.00 19.05 ± 0.21 0.68 ± 0.13 98.82 ± 1.61 
6 0.13 ± 0.08 1.22 ± 0.00 0.34  ± 0.01 19.09 ± 0.25 0.64 ± 0.04 98.01 ± 1.63 
7 0.12 ± 0.09 1.22 ± 0.00 0.33  ± 0.00 15.15 ± 0.31 0.78 ± 0.18 99.37 ± 1.23 
8 0.13 ± 0.08 1.22 ± 0.00 0.34  ± 0.01 15.17 ± 0.28 0.82 ± 0.16 98.60 ± 1.54 
9 0.12 ± 0.11 1.22 ± 0.00 0.34  ± 0.01 15.13 ± 0.26 0.86 ± 0.05 98.96 ± 1.40 
10 0.13 ± 0.10 1.22 ± 0.00 0.33  ± 0.01 15.16 ± 0.26 0.84 ± 0.11 98.27 ± 1.76 
11 0.11 ± 0.09 1.22 ± 0.00 0.33  ± 0.00 15.16 ± 0.31 0.82 ± 0.17 97.12 ± 1.69 
12 0.13 ± 0.08 1.22 ± 0.00 0.34  ± 0.01 15.14 ± 0.29 0.84 ± 0.13 98.67 ± 1.97 
13 0.11 ± 0.09 1.22 ± 0.00 0.41  ± 0.01 25.07 ± 0.26 0.42 ± 0.16 98.15 ± 1.98 
*All values are expressed as mean ± SD, n=3 
 
The swelling study of prepared formula tablets (F1–F13) was 
performed in phosphate buffer pH 7.4 and the results as shown in 
(fig. 1). This condition was made to determine the correlation 
between the swelling index formula tablet (F1 to F13) with drug 
release from formula F1 to F13. The swelling profile tablet in fig. 1 it 
is shown that F1 to F12 were able to swelling for 8 h. Formula F13, 
which did not contain excipient matrix swelling for 120 min, then it 
was disintegrated. Formula F12 with matrix CL12-Co-A-XG 2:1 
showed the slowest swelling profile. Tablets with the excipient 
matrix, when contact with water, the tablets was swelling, then 
around the tablet has formed a gel. The gel which regulated the rate 
of drug release from tablets. Thus, the swelling index tablet affects 
the drug release rate. The greater swelling index tablet, the faster 
release of the drug or vice versa. But the drug release rate was also 
affected by the gel form; the best gel strength would give a slow in 
drug release. Drug released with excipient high amylose starch 
crosslinked were released the drug about 50%, while conventional 
starch could release the drug about 80% for 8 h [7, 8]. 
 
 
Fig. 1: Swelling index tablet with various concentrations of co-processed excipients matrix of crosslinked amylose-xanthan gum for 8 h 
(formula F1-F13). All values are expressed as mean±SD, n = 3 
Ariani et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 6, 151-155 
 
154 
In vitro dissolution studies of all the formulations of sustained 
release tablets of diclofenac sodium were carried out in pH 7.4 
phosphate buffers for 8 h respectively. Drug release profile of 
diclofenac sodium from the matrix as shown in (fig. 2). 
 Formula F1 to F6 was a formula using matrix Co-CLA6-XG with a 
ratio of 1:1, 1:2 and 2:1, and the matrix Co-CLA12-XG with a ratio of 
1:1, 1:2 and 2:1. Formula F7 to F12 was a formula using matrix CL6-
Co-A-XG with a ratio of 1:1, 1:2 and 2:1 and matrix CL12-Co-A-XG 
with a ratio of 1:1, 1:2 and 2:1. Formula F13 was a formulation that 
did not use a matrix comparison, only Avicel pH 102. All formulas 
that use matrix (F1 to F12) could released the drug for 8 h with a 
cumulative drug release was ≤  60%, while formula (F13) could 
release the drug for 2 h of almost 100%.   
 
Fig. 2: In vitro release profile of diclofenac sodium with various concentrations of co-processed excipients matrix of crosslinked amylose-
xanthan gum (formula F1-F13). All values are expressed as mean±SD, n = 3 
 
 
Table 5: Kinetics release data of diclofenac sodium matrix tablets formula F1-F13 
Formula Parameter Zero order First order Higuchi model Korsmeyer-Peppas 
1 r 0.992 ± 0.001 0.938 ± 0.005 0.95 ± 0.005 0.974 ± 0.002 
 n          0.593 ± 0.02 
2 r 0.989 ± 0 0.937 ± 0.004 0.946 ± 0.002 0.969 ± 0.001 
 n          0.596 ± 0.012 
3 r 0.99 ± 0.002 0.946 ± 0.007 0.946 ± 0.006 0.967 ± 0.006 
 n          0.606 ± 0.012 
4 r 0.988 ± 0.001 0.941 ± 0.002 0.942 ± 0.002 0.967 ± 0.006 
 n          0.597 ± 0.012 
5 r 0.993 ± 0.001 0.934 ± 0.003 0.956 ± 0.001 0.976 ± 0.002 
 n          0.599 ± 0.002 
6 r 0.987 ± 0.001 0.943 ± 0.004 0.948 ± 0.002 0.968 ± 0.002 
 n          0.614 ± 0.003 
7 r 0.984 ± 0.002 0.875 ± 0.007 0.977 ± 0.001 0.989 ± 0.001 
 n          0.569 ± 0.014 
8 r 0.991 ± 0.001 0.881 ± 0.004 0.981 ± 0.002 0.993 ± 0.001 
 n          0.572 ± 0.01 
9 r 0.987 ± 0.001 0.865 ± 0.003 0.977 ± 0.003 0.974 ± 0.001 
 n          0.516 ± 0.011 
10 r 0.991 ± 0.002 0.884 ± 0.011 0.979 ± 0.002 0.992 ± 0.001 
 n          0.58 ± 0.013 
11 r 0.993 ± 0 0.906 ± 0.007 0.979 ± 0.004 0.988 ± 0.002 
 n          0.554 ± 0.014 
12 r 0.983 ± 0.003 0.898 ± 0.008 0.981 ± 0.002 0.988 ± 0 
 n          0.55 ± 0.011 
13 r 0.995 ± 0 0.978 ± 0.001 0.958 ± 0 0.925 ± 0.001 
  n                   0.398 ± 0.007 
n = exponent Peppas’s difusion 
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Banakar’s rules are used to explained amount of drug dissolved 
associated with the frequency of drug administration. If the 
dissolved drug percentage ranged 20-45%, the sustained release 
tablet could be used for 32 h, if the percentage of dissolved drug 
ranged 45-75%, it could be used for 16 h and the percentage of drug 
dissolved ranges over 75%, the sustained release preparations could 
used only for 8 h [16]. The results of the percentage of drug 
released for 8 h using Banakar’s rules, the formulas F1 to F6 in the 
range of 45-75%. Formulas F7 to F12 in the range of 20-45%. So, 
formula F1 to F6 showed the controlled release of diclofenac 
sodium for 16 h and formula F7 to F12 used for 32 h. Drug 
released profile from all formulas was calculated and analyzed 
against several kinetics equation (zero order, first order, Higuchi, 
and Korsmeyer-Peppas) to determine the mechanism of drug 
release from the sustained release tablet dosage forms. The values 
of release parameters, n and r (coefficient correlation) are 
inversely related. The results of the calculation of diclofenac 
sodium release kinetics shown in table 5. 
On Korsmeyer-Peppas equation, if n = 0.89, drug release mechanism 
was an erosion of the polymer matrix and the mechanism is named 
as Case II transport. If the value of n is in the range 0.45<n<0.89, 
the release was diffusion-erosion matrix named as an anomalies or 
non-Fickian diffusion. However, if the value of n<0.45, the drug 
release occurs by diffusion and named as Fickian diffusion. If 
n>0.89, the drug release mechanism called super case II transport 
which the release occured by the swelling of the polymer. Drug 
release mechanism of formula F1 to F6, F9, F11 and F13 followed 
zero order kinetics. Then, formula F7, F8, F10 and F12 followed 
Korsmeyer-Peppas mechanism.  
The drug release mechanism of formula F1 to F12 followed 
Korsmeyer-Peppas kinetics with n values are between 0.45 and 
0.89. It means followed non-Fickian diffusion or anomalous, which 
describes the drug release mechanism was controlled by a 
combination of diffusion and erosion. Then, formula F13 has 
n<0.45 so that the drug release followed by Fickian diffusion. 
CONCLUSION 
Diclofenac sodium sustained release tablet could be prepared by 
direct compression method. The swelling index of matrix tablet 
containing Co-CLA6-XG (F1, F2 and F3) and Co-CLA12-XG (F4, F5 
and F6) showed that slower swelling profile than matrix tablet of 
CL6-Co-A-XG (F7, F8 and F9) and CL12-Co-A-XG (F10, F11 and F12). 
Due to the swelling index, then the matrix tablets of formula F1-F6 
could control the diclofenac sodium release effectively 16 h, while 
the matrix tables of formula F7-F12 significantly effective in 
sustaining the drug release for 32 h. The drug release mechanism 
was controlled by diffusion and erosion. It was concluded that 
excipients of Co-CLA-XG and CL-Co-A-XG could be used in the 
formulation of sustained release tablet. 
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